Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novavax Inc.

www.novavax.com

Latest From Novavax Inc.

Enanta Hopes To Succeed In RSV With N-Protein Inhibition Approach

Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.

Clinical Trials Respiratory

Novavax Looks To Secondary Endpoints As Phase III RSV Vaccine Trial Fails

Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?

Clinical Trials Research & Development

What Does 2019 Hold For Biopharma?

Industry executives, consultants and analysts speculate on what they believe the big themes, trends and events will be this year.

C-Suite Speaks Business Strategies

Scrip Asks... What Will 2019 Hold For Biopharma? Part 1: Therapeutic Advances

Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.

Innovation Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novavax Inc.
  • Senior Management
  • Stanley C Erck, Pres. & CEO
    John J Trizzino, SVP, CBO & CFO
    Gregory M Glenn, MD, Pres., R&D
    Russell P Wilson, SVP, Bus. Dev.
    Louis F Fries, MD, CMO
  • Contact Info
  • Novavax Inc.
    Phone: (240) 268-2000
    20 Firstfield Rd.
    Gaithersburg, MD 20878
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register